You are here:

1 mg estradiol/2 mg drospirenone (Angeliq®)


Following a full submission

1 mg estradiol / 2 mg drospirenone (Angeliq) is not recommended for use within NHS Scotland for prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or have contra-indications to, other medicinal products approved for the prevention of osteoporosis.

It maintains bone mineral density, relative to placebo, in post-menopausal women. However, no evidence of cost-effectiveness has been presented.

Drug Details

Drug Name: 1 mg estradiol/2 mg drospirenone (Angeliq®)
SMC Drug ID: 227/05
Manufacturer: Schering Health Care Ltd
Indication: Prevention of osteoporosis
BNF Category:
Sub Category: 6.4 Sex Hormones
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 January 2006